Clinical Trials Logo

Cellulitis clinical trials

View clinical trials related to Cellulitis.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06358846 Not yet recruiting - Diabetic Foot Clinical Trials

Effectiveness of Educational Intervention on Footcare Among Individuals Having Type 2 Diabetes at Slums of Karachi, Pakistan.

Start date: May 15, 2024
Phase: N/A
Study type: Interventional

There are multiple studies conducted in Pakistan that supports the topic of foot care knowledge among individual with type 2 diabetes but all are descriptive cross-sectional studies and investigators cannot develop cause effect relationship out of it. Secondly, there is a lack of documented research on the foot care knowledge shown by people with T2D residing in the slums of Karachi. In order to assess the knowledge intervention among the individual having T2D through qualified diabetes educators and pictorial educational pamphlet along with the standard care of treatment. Consequently, it may aid in the development of effective methods aimed at mitigating foot-related complications among this specific population. Individuals diagnosed with diabetes are required to engage in proactive and structured self-care activities by providing the foot care knowledge in order to effectively manage their condition and mitigate the risk of potential complications. The incorporation of health-deviation knowledge and activities into routine is crucial.

NCT ID: NCT06247761 Not yet recruiting - Scar Clinical Trials

STASSH - TRAUMA - Absorbable vs Non-Absorbable Sutures in Trauma Hand Surgery

STASSH-TRAUMA
Start date: January 29, 2024
Phase: N/A
Study type: Interventional

An RCT will be set up to compare outcomes between two groups of hand surgery patients. These are: • Emergency hand surgery patients - randomized to either absorbable or non-absorbable suture. The primary outcomes investigated will be: • Infection occurrence The secondary outcomes will be: - Scar appearance at 1 week and 6-8 weeks (assessed from photographs and scar scoring scale) - Wound inflammation as a percentage of wound length at day 7 post surgery. - Patient symptoms at 1 week (assessed from patient questionnaire) - Patient symptoms at 6-8 weeks (assessed from patient questionnaire) - QDASH Score at 1 week (assessed from patient questionnaire) - QDASH score at 6-8 weeks (assessed from patient questionnaire) - Occurrence of other complications (assessed from the above photographs, the above questionnaires and from nurse and doctor led reports of wound breakdown and other complications)

NCT ID: NCT06170983 Not yet recruiting - Skin Infection Clinical Trials

Skin Inflammation and PK of Azithromycin

AZI_IMQ_LPS
Start date: January 1, 2024
Phase: N/A
Study type: Interventional

This study will investigate the tissue distribution of azithromycin in healthy, artificially inflamed and actually infected tissue of humans.

NCT ID: NCT06023550 Not yet recruiting - Sinusitis Clinical Trials

Complicated Infections in Otorhinolaryngology

ENT_infect
Start date: August 2024
Phase:
Study type: Observational [Patient Registry]

This observational study aims to learn more about complicated infections treated by otorhinolaryngologists. The main questions to answer are: - What is the management of complicated sinonasal infections in Ljubljana, Slovenia, - What is the management of complicated ear and temporal bone infections in Ljubljana, Slovenia, - What is the management of complicated neck soft tissue infections in Ljubljana, Slovenia, - What is the management of complicated laryngeal infections in Ljubljana, Slovenia Participants will receive standard treatment according to the established evidence-based clinical practice.

NCT ID: NCT05899140 Not yet recruiting - Clinical trials for Staphylococcal Infections

Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial

SoTiClin
Start date: February 1, 2024
Phase: Phase 4
Study type: Interventional

This is an exploratory study to evaluate the effect of adjunctive clindamycin in the treatment of skin and soft-tissue infections due to Staphylococcus aureus in patients from Sierra Leone. The study hypothesizes that clindamycin, when added to routine treatment, will lead to a more rapid clinical resolution and less frequent recurrences of infection.

NCT ID: NCT05828550 Not yet recruiting - Clinical trials for Patients withInfections Caused by S.Aureus Like Skin Infections , Chest Infections , Surgical Site Infections , and Urinary Tract Infections

Detection of Efflux Pump Genes Mediating Ciprofloxacin Resistance in Staphylococcus Aureus Isolates in Sohag University Hospitals

Start date: May 2023
Phase: N/A
Study type: Interventional

Among multidrug-resistant bacteria, Methicillin-resistant Staphylococcus aureus (MRSA) isolates were recognized to be an important mortality factor in hospital infections and a major concern in health-care and community settings . The antibiotic-resistant of S. aureus is extended by various bacterial strategies, including limiting uptake of the drug, alteration of the drugtargets, production of druginactivating enzymes and the activation of efflux pumps that effectively remove antibiotics . Relying on the type of antibiotics, bacteria can apply one or more strategies. Specifically, localization of resistance genes in transferable genetic elements, such as plasmid and transposons , causing Horizontal transfer of resistance genes between bacterial strains . MRSA strains are resistant to nearly all beta-lactam antibiotics by producing an alternative penicillin-binding protein known as PBP2a . This protein is encoded by the mecA gene and has a low affinity to manybeta-lactam antibiotics. Furthermore, these strains often show resistance to a wide range of antibiotics . The use of fluoroquinolone for the effective infectious therapy is limited by presence of fluoroquinolone resistance . There are two mechanisms causing resistance to fluoroquinolone. The first one is attributed to mutations occurring in the quinolone-resistance determining region (QRDR) of topoisomerase IV encoded by grlA/grlB and DNA gyrase encoded by gyrA/gyrB; these mutations decrease the affinity ofthe drug. The other mechanism is mediated by efflux pumps which is less recognized . Recently, several efflux pumps have been identified for S. aureus including efflux pumps encoded by chromosome or plasmids. The efflux pumps norA, norB, norC, mdeA, sepA, mepA, sdrM and lmrS are encoded by chromosome while qacA/B, qacG, qacH, qacJ and smr are plasmid-encoded . Efflux pumps could be specialized for specific substrate or mobilized a wide varieties of different antibiotic classes . Despite, efflux pumps can potentially increase resistance to antibiotics in clinical isolates of S. aureus, few studies have been evaluated the individual and collective participation of the efflux system in resistant isolates . Therefore the aim of the study is to detect ciprofloxacin resistant strains of staphylococcus aureus isolates and to detect efflux pump genes ( norA , norB and norC ) mediating resistance in such strains.

NCT ID: NCT05584007 Not yet recruiting - Cellulitis of Leg Clinical Trials

Cellulitis Optimal Antibiotic Treatment

COAT
Start date: June 1, 2023
Phase: Phase 3
Study type: Interventional

To determine whether a short course of oral flucloxacillin (5 days) is non-inferior to a standard course (7 days) in terms of pain over days 6-14 (indicative of persistence or recurrence associated with the symptoms of most importance to patients) in adults with cellulitis of the leg presenting in primary care.

NCT ID: NCT05473325 Not yet recruiting - Obesity Clinical Trials

Benchtop NMR Spectroscopy for Assessment of Clinical Human Pathologies (BRANCH-P STUDY)

BRANCH-P
Start date: January 1, 2023
Phase:
Study type: Observational

This research programme seeks to combine the resources of NHS primary care, with the leading spectroscopic work in low-magnetic fields of the Wilson Group (Nottingham Trent University) to demonstrate the potential for benchtop Nuclear Magnetic Resonance (NMR) spectroscopy in human clinical pathology. This is an instrument assessment study for point of care viability which will also result in enhanced patient care (pending their consent) in blood screenings and metabolic health data.

NCT ID: NCT03985475 Not yet recruiting - Skin Infections Clinical Trials

Identification of the Cutaneous Microbiota in Patients With Cutaneous Infection (MICROBIOTA)

Start date: July 1, 2019
Phase:
Study type: Observational [Patient Registry]

Identify the cutaneous microbiota on a cutaneous lesion (cellulite, wound, rash, etc.) on a swab, biopsies or abscess puncture and on "healthy" skin on a skin swab performed for cutaneous mapping to search for staphylococcal deposits.

NCT ID: NCT03917134 Not yet recruiting - Hysterectomy Clinical Trials

Prevention of Vaginal Cellulitis or Vaginal Cuff Abscess After Laparoscopic Hysterectomy

Start date: May 1, 2019
Phase: N/A
Study type: Interventional

Operative site infection remains the most common complication after performing a gynecological procedure, and has a great implication in the morbidity and mortality of patients. Gynecological procedures, including laparoscopic hysterectomy, represent a unique challenge due to the amount of microorganisms found at the skin level of the vagina or the endocervix. However, there is no clear evidence that the complication decreases with the use of postoperative antibiotics. With the completion of this study, a multicentre triple-blind controlled randomized controlled trial is intended to determine the behavior of the application of this intervention. Patients who attend an outpatient clinic with benign pathology will be selected, in which indication of laparoscopic hysterectomy, consents are completed and research content is widely explained. Prior to surgery, the sample is taken for a gram of vaginal discharge and in the post-surgical phase delivery of the medication will be performed. Follow-up will be carried out by surgical control and by telephone. The investigator intend to find that with the prophylaxis not only of presurgical cephalosporin, but with the formulation of metronidazole ovules in the postoperative, the incidence of laparoscopic post-hysterectomy vaginal abscess and cellulitis of cuff is reduced.